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Abstract
Background: Infection plays a role in the pathogenesis of many human malignancies. Whether prostate cancer
(PCa) - an important health issue in the aging male population in the Western world - belongs to these conditions
has been a matter of research since the 1970 s. Persistent serum antibodies are a proof of present or past
infection. The aim of this study was to compare serum antibodies against genitourinary infectious agents between
PCa patients and controls with benign prostate hyperplasia (BPH). We hypothesized that elevated serum antibody
levels or higher seroprevalence in PCa patients would suggest an association of genitourinary infection in patient
history and elevated PCa risk.
Methods: A total of 434 males who had undergone open prostate surgery in a single institution were included in
the study: 329 PCa patients and 105 controls with BPH. The subjects’ serum samples were analysed by means of
enzyme-linked immunosorbent assay, complement fixation test and indirect immunofluorescence for the presence
of antibodies against common genitourinary infectious agents: human papillomavirus (HPV) 6, 11, 16, 18, 31 and
33, herpes simplex virus (HSV) 1 and 2, human cytomegalovirus (CMV), Chlamydia trachomatis, Mycoplasma
hominis, Ureaplasma urealyticum, Neisseria gonorrhoeae and Treponema pallidum. Antibody seroprevalence and
mean serum antibody levels were compared between cases and controls. Tumour grade and stage were correlated
with serological findings.
Results: PCa patients were more likely to harbour antibodies against Ureaplasma urealyticum (odds ratio (OR) 2.06;
95% confidence interval (CI) 1.08-4.28). Men with BPH were more often seropositive for HPV 18 and Chlamydia
trachomatis (OR 0.23; 95% CI 0.09-0.61 and OR 0.45; 95% CI 0.21-0.99, respectively) and had higher mean serum
CMV antibody levels than PCa patients (p = 0.0004). Among PCa patients, antibodies against HPV 6 were
associated with a higher Gleason score (p = 0.0305).
Conclusions: Antibody seropositivity against the analyzed pathogens with the exception of Ureaplasma does not
seem to be a risk factor for PCa pathogenesis. The presence or higher levels of serum antibodies against the
genitourinary pathogens studied were not consistently associated with PCa. Serostatus was not a predictor of
disease stage in the studied population.
Background
Prostate cancer (PCa) is one of the most important
health issues in the aging male population, especially in
the industrialized Western world. In the EU in 2006, it
accounted for approximately 20% of all noncutaneous
cancers [1]. In the United States, 217.730 new cases
were estimated to occur in 2010 (28% of all new cancer
cases in men except for basal and squamous cell skin
carcinomas) and 32.050 men were expected to die from
PCa (11% of all cancer-related deaths) [2].
Research on the etiology of human cancer has found
evidence for 15-20% of them being caused by an infec-
tious agent. Whether PCa or at least a subgroup of PCa
cases are associated with infection has been a matter of
debate since the 1970 s. With the widespread use of
sophisticated serological assays and molecular biology
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several studies have been published in the past two dec-
ades giving a better insight into the matter. Many of
them have focused on a single pathogen only [3-9].
We have conducted an epidemiological study of sev-
eral most common genitourinary pathogens among PCa
and benign prostate hyperplasia (BPH) patients. The
aim of the study was to elucidate whether the preva-
lence of antibody seropositivity and/or antibody levels
differ between these two groups of patients. We
hypothesized that elevated serum antibody levels or
higher seroprevalence in PCa patients would suggest an
association of genitourinary infection in patient history
and elevated PCa risk.
Methods
Study population
This is a hospital-based case-control study. The study
population consisted of a total of 434 Caucasian males
who had been treated with open prostate surgery in the
Department of Urology of the 3
rd Faculty of Medicine,
Charles University in Prague in the period 2004-2010.
The institution is a public hospital with a non-selective
admission policy based on a defined catchment area.
Patients underwent open radical retropubic prostatect-
omy (RRP) modified by Reiner and Walsh [10,11] for
clinically localized PCa or simple transvesical prostatect-
omy (SP) as described by Fuller and Culp [12,13] for
BPH. No transurethral resection of the prostate (TURP)
or needle-biopsy specimens were used in the study as
both methods only deliver so little tissue that small foci
of PCa can be missed. In 5 cases, percutaneous cysto-
lithotripsy was performed along with SP. All patients
were free of urinary tract infection symptoms and had a
negative urine culture at the time of surgery. Those with
untreatable bacteriuria (eg. for bladder stones and/or an
indwelling catheter) were treated with antibiotics in the
perioperative period.
Study population characteristics are summarized in
Table 1. See patient flow diagram (Figure 1) for recruit-
ment and pre-enrolment phase details.
A written informed consent, approved by the Internal
Grant Agency of the Ministry of Health of the Czech
Republic and by the Ethical Committee of the 3
rd
Faculty of Medicine, Charles University in Prague (an
IRB-like body which also approved the study), was
obtained from all patients.
Tissue sample handling
Immediately after removal from the anatomical location,
the specimens were referred to the Department of
Pathology for examination: radical prostatectomy speci-
mens were processed according to the scheme described
by Montironi [14]: the external surface of the prostate
was painted with ink to indicate surgical margins, semi-
nal vesicles were amputated and embedded. Then the
apical and bladder neck margins were removed and sec-
tioned parallel to the urethra and submitted for the
examination of margins. The rest of the prostate was
sliced at 5 mm intervals perpendicularly to the urethra
and examined. Tissue specimens obtained from transve-
sical prostatectomy were sectioned in 5 mm slices and
representative sections from each lobe (a minimum of
Table 1 The study population characteristics
Patient group
PCa BPH
Total number of patients 329 patients 105 patients
Mean age (years) 64 (39-81) 72 (54-87)
<60 76 (23.1%) 7 (6.7%)
60-69 191 (58.1%) 33 (31.4%)
70-79 61 (18.5%) 43 (41.0%)
>79 1 (0.3%) 22 (21.0%)
Mean PSA (ng/mL) 9.0 (0.8-35.4) 7.5 (0.9-39.0)
0-4.0 37 (11.5%) 25 (33.8%)
4.1-10.0 176 (54.8%) 35 (47.3%)
10.1-20.0 94 (29.3%) 9 (12.2%)
>20.0 14 (4.4%) 5 (6.7%)
Overall demographic and clinical characteristics of the studied population.
PCa prostate cancer, BPH benign prostate hyperplasia, PSA prostate specific
antigen.
Total eligible patients: 
498
Refusal by surgeon: 35
Total recruited: 435
329 PCa
319 RRP 116 SP
105 BPH
1 excluded: no 
cancer tissue 
found (pT0)
11 incidental PCa findings (pTX)
Refusal by patient: 13
Unavailability of serum 
sample: 15
Figure 1 Patient flow diagram. A scheme of the patient
recruitment process. RRP radical retropubic prostatectomy, SP
simple transvesical prostatectomy, PCa prostate cancer, BPH benign
prostate hyperplasia.
Hrbacek et al. BMC Cancer 2011, 11:53
http://www.biomedcentral.com/1471-2407/11/53
Page 2 of 10three sections from each lobe, or one section per 10 g of
tissue) were examined [15]. Tissue specimens were rou-
tinely fixed with 4% buffered formalin and embedded in
paraffin. Microscopic slides were stained with hematoxy-
lin and eosin and evaluated by optical microscopy.
A single pathologist experienced in urogenital pathology
performed microscopic evaluation of the slides. The
morphological parameters were recorded as follows: his-
tological type of cancer, if present (based on WHO clas-
sification [16]); Gleason score (GS) with primary,
secondary and tertiary, if appropriate, grades (according
to 2005 ISUP Consensus Conference [17]); pathological
stage [18]; evaluation of tumour extension, local inva-
sion into periprostatic tissue or seminal vesicles, peri-
neural spread, venous and/or lymphatic vessel invasion
and surgical margin status [19]. PCa was present in 329
surgical specimens, 105 were classified as BPH without
any malignant structures. Table 2 summarizes GS and
staging information for the PCa group. Fasting periph-
eral venous blood samples were drawn between 6 and
8 a.m. on the day of surgery and centrifuged at 2000
rpm for 20 minutes. The aliquots were kept frozen at
-80°C until analysis.
Laboratory analyses
The presence of antibodies to Chlamydia trachomatis
(C. trachomatis), herpes simplex virus (HSV) 1 and 2,
human cytomegalovirus (CMV), Neisseria gonorrhoeae
(N. gonorrhoeae), Treponema pallidum (T. pallidum),
Mycoplasma hominis (M. hominis) and Ureaplasma
urealyticum (U. urealyticum) were detected by means of
enzyme-linked immunoanalysis (ELISA), complement
fixation test (CFT) or indirect immunofluorescence (IF)
using commercially available, CE marked kits according
to the manufacturers’ recommendations. Table 3 gives a
detailed description of the kits. Specific antibodies to
HPV were detected by means of an in-house method
using virus-like particles (prepared in a recombinant
baculovirus/insect cells system) as antigens [20]. Labora-
tory personnel were blinded to case/control status of the
samples.
Preparation of virus-like particles (VLPs)
Insect cells Sf9 were grown in suspension cultures in
TNM-FH insect medium (Sigma). About 4 × 10
9 of
cells were infected by recombinant baculovirus at MOI
10 PFU per cell. Various recombinant baculoviruses car-
ried the genetic information for L1 capsid protein of
specific HPV types. Seventy-two hours after infection,
the cells were harvested, washed with phosphate-buf-
fered saline (PBS) and stored at -20°C. Cell pellets were
resuspended in 40 ml of extraction buffer (10 mmol/l
MgCL2, 50 mmol/l CaCl2, 150 mmol/l NaCl, 0.01% Tri-
ton X-100, 20 mmol/l HEPES, pH 7.4) and sonicated
3x30 minutes on ice, the suspension was pelleted, the
pellet was resuspended in 40 ml of extraction buffer and
sonication was repeated. Cesium chloride was added to
combined supernatants to the final concentration of
30% and ultra-centrifuged for 22 hours at 45,000 rpm at
18°C. The upper band was then separated by ultra cen-
trifugation on CsCl step gradient (36%-30.5%-16%) for
4 hours at 35,000 rev/min. at 18°C. The band was
removed and subjected to SDS PAGE to determine pro-
tein concentration and Western blotting, and ELISA
with corresponding VLP-specific monoclonal antibodies
to prove the presence of the respective antigen.
Detection of HPV-specific antibodies
The presence of antibodies to the antigens derived from
HPV-specific proteins was tested using the enzyme-
linked immunosorbent assay (ELISA). VLPs mimicking
HPV types 6, 11, 16, 18, 31 and 33 were used as anti-
gens. Briefly, wells of microtiter plates (Polysorp NUNC
immunoplate, Thermo Fisher Scientific, Denmark) were
coated with 50 μl of purified VLP (2 μg/ml) in PBS at
37°C for 2 hours and at +4°C overnight. All subsequent
incubations were performed at +37°C for 1 hour.
Unbound antigen was removed, nonspecific binding
sites were blocked by incubation with 1% bovine-serum
albumin (BSA) in PBS, and the wells were incubated in
duplicate with 100 μl of human sera diluted 1:25 in
washing buffer (PBS, 0.21 mol/l NaCl, 0.1% Triton X-
100) with 1% of BSA. Following incubation, the antibo-
dies bound were detected with donkey anti-human IgG
(H and L chain), covalently linked to horseradish peroxi-
dase (Jackson ImmunoResearch Laboratories, Inc, West
Grove, PA, USA), in the same buffer (1:7,500) and the
reaction was visualized by adding 100 μlo fas u b s t r a t e
buffer (50 mmol/l phosphate-citrate buffer, pH 5.0) con-
taining 0.04% o-phenylenediamine and 0.006% hydrogen
peroxide. The color reaction was stopped by 100 μlo f
Table 2 Gleason score and tumour stage in prostate
cancer cases
Tumour grading
Median Gleason score 6
2-6 169 (51.4%)
7 124 (37.7%)
8-10 36 (10.9%)
Tumour pathological stage
≤pT2a 18 (5.5%)
pT2b 5 (1.5%)
pT2c 134 (40.7%)
pT3a 98 (29.8%)
≥pT3b 63 (19.1%)
pTX 11 (3.4%)
Hrbacek et al. BMC Cancer 2011, 11:53
http://www.biomedcentral.com/1471-2407/11/53
Page 3 of 102m o l / lH 2SO4 and optical densities at 492 and 630 nm
were read with an Infinite 200 microplate reader
(TECAN, Austria). Background reactivity was deter-
mined in wells without antigen. Their absorbances were
subtracted from the corresponding values obtained in
the presence of antigen. Control sera known to be posi-
tive or negative were tested on each plate. The cut-off
(CO) level, above which the optical density values were
considered positive, was represented by a mean absor-
bance plus 2 standard deviations (SD) after eliminating
the outliers - samples with absorbances higher than the
calculated cut-off value - and the calculation was
repeated until the absorbances of all remaining samples
were lower. The means and SDs were calculated for
each antigen/plate separately. All ELISA results are
represented as a ratio between the absorbance obtained
with the tested sample and the appropriate cut-off value
(OD index), which expresses the strength of antibody
response (antibody levels). To confirm the results, all
samples within 10% above the CO value as well as
about one quarter of all serum samples were retested.
Samples with OD index values ≤ 1.0 were considered
not reactive.
Statistical analyses
Descriptive statistics was employed to assess demo-
graphic and clinical variables in all subjects. Local stage
and tumour aggressiveness by GS were calculated in
PCa patients.
We established seropositivity rates for each individual
pathogen in cases and in controls. Percentages of seropo-
sitive individuals were compared using Fisher’s exact test.
T h em e a ns e r u ma n t i b o d yl evels represented by OD
indexes were calculated and compared between the two
g r o u p sf o rH P V ,H S V ,C M Va n dC .t r a c h o m a t i sw h e r e
ELISA allows for quantitative assessment using Wilcox-
on’s (nonparametric) test.
We were looking for a possible association between
seropositivity and PSA level, seropositivity and tumour
GS, and seropositivity and localized vs. locally advanced
d i s e a s eu s i n ga p p r o p r i a t el o g i s t i cr e g r e s s i o nm o d e l s .
Throughout the paper, 5% significance level is meant
whenever we mention statistical significance. All statisti-
cal analyses were computed using statistical software “R”
http://www.r-project.org/.
This paper’s contents were developed with regard to
current recommendations on reporting of observational
studies [21].
Results
In a total of 434 study subjects, there were 329 PCa
patients (mean age 64 years) and 105 controls with BPH
(mean age 72 years). PCa had been present in 11
patients out of 116 who underwent SP. These incidental
carcinomas were included in the PCa group for case vs.
control comparisons but were excluded from analyses
where exact local staging was required (see Figure 1).
The mean PSA levels were 9.0 and 7.5 ng/mL among
subjects and controls, respectively (Table 1). Among
PCa patients, 47.7% were diagnosed with localized dis-
ease and 52.3% had locally advanced cancer. One half of
the tumours (51.4%) were low-grade lesions GS 2-6,
while one tenth (10.9%) wereh i g h - g r a d el e s i o n sG S8 -
10 (Table 2).
The seropositivity rates and mean serum antibody
levels are summarized in Table 4. U. urealyticum anti-
bodies were significantly more common in PCa cases
than in controls (OR 2.06; 95% CI 1.08-4.28). Conver-
sely, the seropositivity rates for HPV 18 and C. tracho-
matis were significantly higher in BPH patients than in
the PCa group using Fisher’s exact test (OR 0.23; 95%
CI 0.09-0.61 and OR 0.45; 95% CI 0.21-0.99, respec-
tively). The mean serum antibody levels for CMV were
higher in the BPH than in the PCa group using
Table 3 Commercially available kits used for the detection of antibodies
Pathogen Method Kit Manufacturer
Cytomegalovirus ELISA ETI-CYTOK-G DiaSorin S.p.A., Saluggia, Italy
Herpes simplex virus
type 1
ELISA Captia™HSV 1 IgG Trinity Biotech plc, Bray, Ireland
Herpes simplex virus
type 2
ELISA HerpeSelect(R) 2 ELISA IgG FOCUS Diagnostics, Cypress, CA, USA
Chlamydia trachomatis ELISA Chlamydia Trachomatis IgG -
ELISA
NovaTec Immunodiagnostica GmbH, Dietzenbach,
Germany
Mycoplasma hominis Indirect immunofluorescence
test
Anti-Mycoplasma Hominis IIFT
(IgG)
EuroImmun, Lübeck, Germany
Ureaplasma urealyticum Indirect immunofluorescence
test
Anti-Ureaplasma Urealyticum IIFT
(IgG)
EuroImmun, Lübeck, Germany
Neisseria gonorrhoeae Complement fixation test Complement fixation test
Neisseria gonorrhoeae
Serion Immunodiagnostica GmbH, Würzburg,
Germany
Treponema pallidum ELISA Syphilis EIA II (TA] Newmarket Laboratories Ltd, Kentford, UK
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Table 4). For other pathogens, the differences in the
seroprevalence and mean serum antibody levels were
not statistically significant (Figure 2).
We then analyzed the PCa cases alone with regard to
serostatus and disease characteristics. Patients seroposi-
tive for HPV 6 were more likely to have higher GS than
men without antibodies to HPV 6 (mean GS 6.45 vs.
6.75; p = 0.0305); other differences in GS were not
demonstrated. No statistically significant difference was
noted in the mean PSA level between the seropositive
and seronegative (for each pathogen) individuals. The
mean serum antibody levels did not differ significantly
between the patients with localised disease (≤pT2c) and
locally advanced PCa (≥pT3a). These observations did
not change when age was taken as an additional variable
and linear/logistic regression models were employed
(data not shown).
Discussion
Clinically insignificant foci of PCa are harboured by
prostates of 80% of men over 80 years old [22]. The
only way to examine the prostate in its entirety and to
divide the subjects into the case and control groups is
the use of open surgery derived specimens. This
approach has not been used so far. No needle biopsy or
TURP which can only deliver a small portion of pro-
static tissue allows the clinician to rule out the possibi-
lity of cancer being present in the rest of the prostate
gland. Approximately 1/10 of allegedly benign prostates
scheduled by a surgeon for SP turned out as cancerous
in our study, which is in line with the 4-20% incidental
prostate cancer rate cited in the literature [23]. Most of
the previous studies identified cases in cancer registries
while controls were defined either by absence of PCa
diagnosis [7,24-27] or as “cancer free” a tt h et i m eo f
analysis [6,8,28]. This approach can be misleading,
because it is the nature of the disease to evolve as sub-
clinical lesions for years or even decades and inclusion
of these patients into the control group may have biased
the results towards the null. Only few authors assessed
the controls more deeply, i.e. by histopathologic exami-
nation of prostate tissue [3-5,29,30] obtained by open
surgery, TURP or prostate biopsy. Inherently, a needle
biopsy or TURP can only confirm but by no means
exclude the diagnosis of cancer. Some researchers gath-
ered details of tumour characteristics such as GS and
staging by TNM classification [5,8,26,28-32], but in
most cases they do not report these data.
The exclusive use of radical prostatectomy-derived
specimens allowed for the assessment of seropositivity
with regard to exact local staging of the disease. This is
t h ef i r s ts t u d yt oo u rk n o w l e d g et ol o o ka tt h ei s s u es o
closely. Had there been an association between local dis-
ease stage and serostatus, it would have been demon-
strated. However, no statistically significant differences
were noted. Similarly, no differences were found in the
mean PSA levels and mean GS between the seropositive
and seronegative PCa patients (with the exception of
HPV 6, as mentioned above and discussed later on in
this section). The picture remained the same when age
was taken as an additional variable.
Table 4 Antibody seropositivity rates and mean serum antibody levels
Seroprevalence rate Mean serum levels OD/CO
PCa BPH OR 95% CI PCa BPH p
HPV 6 77 (24.1%) 21 (20.8%) 1.21 0.71-2.12 2.608 3.162 0.0964
HPV 11 40 (12.5%) 15 (14.9%) 0.82 0.44-1.60 2.554 2.259 0.9698
HPV 16 16 (5.0%) 10 (9.9%) 0.48 0.21-1.13 3.470 3.251 0.8743
HPV 18 8 (2.5%) 10 (9.9%) 0.23 0.09-0.61 1.496 1.365 0.9290
HPV 31 19 (5.9%) 8 (7.9%) 0.73 0.32-1.83 2.616 3.640 0.1053
HPV 33 7 (2.2%) 5 (5.0%) 0.43 0.13-1.48 2.156 3.620 0.3434
CMV 264 (80.2%) 91 (86.7%) 0.62 0.32-1.14 3.839 4.407 0.0004
HSV 1 313 (95.1%) 99 (94.3%) 1.19 0.42-2.97 3.760 3.832 0.9649
HSV 2 42 (12.8%) 14 (13.3%) 0.95 0.51-1.88 5.362 4.859 0.8056
Chlamydia trachomatis 18 (5.5%) 12 (11.4%) 0.45 0.21-0.99 1.281 1.210 0.6560
Mycoplasma hominis 60 (18.2%) 15 (14.3%) 1.34 0.74-2.55 NA NA -
Ureaplasma urealyticum 64 (19.5%) 11 (10.5%) 2.06 1.08-4.28 NA NA -
Neisseria gonorrhoeae 20 (6.1%) 6 (5.7%) 1.07 0.44-2.99 NA NA -
Treponema pallidum 1 (0.3%) 0 (0%) NA NA NA NA -
Antibody seropositivity rates for different genitourinary pathogens in cases and controls. Only reactive serum samples (OD/CO > 1.0) were considered for the
calculation of mean serum antibody levels. PCa prostate cancer, BPH benign prostate hyperplasia, OR odds ratio, CI confidence interval, OD/CO optical density/
cut-off, HPV human papillomavirus, CMV human cytomegalovirus, HSV herpes simplex virus, NA not applicable.
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hypothesized that PCa could be caused by an infectious
agent, research studies have been conducted in order to
confirm or rule out this possibility. Taylor et al.
reviewed the literature related to sexually transmitted
diseases (STDs) and PCa from 1966 to 2004 identifying
6022 unique PCa cases and 7320 controls and con-
cluded that having had any STD was associated with an
elevated PCa risk: odds ratio (OR) of 1.48, 95% confi-
dence interval (CI) 1.26-1.73 [34]. A large recent pro-
spective study by Huang et al., however, did not find an
association of PCa with a specific STD and a borderline
association with any vs. none [26]. Whereas C. tracho-
matis, HPV 16 and 18, HSV 2, CMV and human her-
pesvirus 8 were ascertained by serology in this study, a
history of syphilis and gonorrhoea was only self-
reported.
HPV is a sexually transmitted pathogen which has
been the most extensively investigated one because of
its association with cervical and a part of other anogen-
ital neoplasms [32]. We have identified 12 epidemiologi-
cal studies related to HPV and PCa, a vast majority of
them being case-control studies putting together over
4,700 PCa cases and 7,300 controls. No more than two
of them [24,29] found an association between PCa and
HPV 18 and 33, respectively, whereas the others did not
(see Table 5 for details). In our study population, HPV
18 antibodies were more common in men with BPH
than in PCa patients. Such an inverse association has
not been reported so far.
The seropositivity rates reported in our study were
5.0% and 2.5% in PCa patients for HPV 16 and 18,
respectively, and 9.9% for both antigens in the BPH
group (Table 4). This coincides well with the estimated
10.2% HPV 16 seroprevalence in the US male popula-
tion aged 50-59 years [35].
HPV 6 is associated with benign skin lesions of the
genitourinary tract. This genotype was demonstrated in
up to 90% of genital warts [36]. To our knowledge, no
previous study investigated the association of HPV
6/11 and PCa nor suggested the virus’ potential to
induce a more malignant phenotype of PCa cells. How-
ever, these two serotypes have been associated with
malignant transformation of recurrent respiratory
papillomatosis [37]. Our finding of a higher mean GS,
i.e. increased aggressiveness of the prostate tumour in
the presence of HPV 6 antibodies, would require
further validation.
Infection with certain herpesviruses has been asso-
ciated with several human cancers. A link has been found
between HSV 1 and oral cancer, while HSV 2 seems to
be a cofactor to HPV in the etiology of invasive cervical
Figure 2 Mean serum antibody levels. Boxplots comparing serum antibody level medians (thick horizontal lines) of cases and controls. Upper
and lower horizontal box lines represent the 25
th and 75
th percentiles. Outliers are marked as dots. CMV human cytomegalovirus, HSV herpes
simplex virus, HPV human papillomavirus, BPH benign prostate hyperplasia, PCa prostate cancer.
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Page 6 of 10Table 5 Overview of previously published case-control serologic studies of genitourinary pathogens with regard to
prostate cancer risk
Author Year Pathogen
studied
No. of
subjects with
PCa
% sero-
positive
No. of controls
without PCa
% sero-
positive
RR/
OR
95%
CI
Evidence of
association
Method
Sutcliffe
[30]
2010 HPV 16 616 14.5 616 13.7 OR
1.07
0.77-
1.48
no ELISA
HPV 18 616 3.3 616 3.7 OR
0.87
0.47-
1.63
no
HPV 31 616 12.3 616 10.8 OR
1.15
0.8-
1.64
no
Dennis
[27]
2009 HPV 16/18 267 18.7 267 16.9 OR
1.13
0.73-
1.75
no ELISA
Huang [26] 2008 HPV 16 765 10.1 915 10.6 OR
0.9
0.7-
1.3
no ELISA
HPV 18 765 9.4 915 8.1 OR
1.2
0.8-
1.7
no
Sitas [9] 2007 HPV 16 205 68.0 673 58.0 OR
1.33
0.86-
2.07
no ELISA
Sutcliffe
[28]
2007 HPV 16 691 7.5 691 8.8 OR
0.83
0.57-
1.23
no ELISA
HPV 18 691 6.1 691 5.8 OR
1.04
0.66-
1.64
no
HPV 33 691 7.2 691 6.4 OR
1.14
0.76-
1.72
no
Korodi [8] 2005 HPV 16 799 6.0 2596 6.0 OR
0.9
0.64-
1.26
no ELISA
HPV 18 799 3.0 2595 4.0 OR
0.79
0.49-
1.26
no
HPV 33 800 9.0 2596 7.0 OR
0.99
0.72-
1.38
no
Adami [29] 2003 HPV 16 238 13.0 210 15.0 OR
0.7
0.4-
1.3
no ELISA
HPV 18 238 12.0 210 12.0 OR
0.9
0.5-
1.9
no
HPV 33 238 29.0 210 23.0 OR
1.6
1.0-
2.7
yes
Rosenblatt
[32]
2003 HPV 16 642 9.2 570 8.8 OR
1.06
0.71-
1.57
no ELISA
HPV 18 642 3.4 570 2.5 OR
1.36
0.69-
2.69
no
Hayes [31] 2000 HPV 16 276 6.9 295 5.1 OR
1.4
0.7-
2.8
no ELISA
Hisada [6] 2000 HPV 16 48 42.0 63 30.0 OR
2.7
0.9-
7.9
no ELISA
Dillner [23] 1998 HPV 16 165 4.0 290 2.0 RR
2.4
0.75-
7.58
no ELISA
HPV 18 165 10.0 290 4.0 RR
2.6
1.17-
5.75
yes
HPV 33 164 4.0 289 6.0 RR
0.7
0.26-
1.66
no
Strickler [5] 1998 HPV 16 63 1.6 144 4.9 NS NS no ELISA
Dennis
[26]
2009 Ch.
trachomatis
267 14.6 267 11.6 OR
1.35
0.79-
2.31
no Microimmuno-
fluorescence
Huang [25] 2008 Ch.
trachomatis
765 11.2 915 9.7 OR
1.2
0.9-
1.6
no ELISA
Sutcliffe
[27]
2007 Ch.
trachomatis
691 4.0 691 3.5 OR
1.13
0.65-
1.96
no ELISA
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to infection of the genitourinary tract is a commonplace.
HSV 2 is seldom completely cleared from the body. Anti-
body levels may fluctuate over time, especially after clini-
cal relapses, but the exact dynamics is not known [27]. In
the U.S., 51.0% of persons over 12 years were seropositive
for HSV 1, 5.3% for HSV 2 and in 16.6%, antibodies spe-
cific to both virus types were present [39]. The HSV 2
prevalence is highest in some African countries, reaching
80% in persons ≥35 years [40].
Sexual contact is a major route of CMV transmission
in adults. Increased CMV rates are associated with
increased history of sexually transmitted diseases. Recent
data indicate that CMV has multiple oncogenic proper-
ties: it promotes mutagenesis, angiogenesis and cell
invasion [41]. The CMV seroprevalence increases with
age, reaching approximately 91% among persons older
than 80 years [42]. Little is known about the relation-
ship between CMV and PCa risk. The only relevant
s t u d yw eh a v ei d e n t i f i e dd i dn o ts h o we v i d e n c eo fa n
association of CMV seropositivity and PCa incidence
[26]. Our data suggest that PC cases have lower anti-
body levels against CMV than BPH patients.
C. trachomatis is one of the most common bacterial
STDs worldwide. It causes urethritis, epididymitis and
prostatitis in males. In up to 50% of infected men and
70-80% of infected women, the infection is clinically
inapparent [43]. In four recent epidemiological studies
of several hundred cases and controls each [24,26-28],
no association between chlamydial antibodies and PCa
was found. One large study [7], however, shows a
significant inverse association (OR 0.69, 95% CI 0.51-
0.94) between chlamydial antibodies and PCa and so do
our data. The seroprevalence we have established is con-
cordant with the data reported previously [44].
The increased antibody prevalence and higher serum
antibody levels we are reporting do not suggest the role
of infection in PCa pathogenesis. They do indirectly
support a concept of BPH being product of immune
inflammatory processes, an idea based on a growing
amount of evidence [45]. The trigger point for an
increased and possibly self-repeating, pathological
immune response would be infection of the genitourin-
ary tract by these pathogens [46].
A study of Takeyama suggested that M. hominis can
trigger inflammation in the prostate by inducing inter-
leukin-8 secretion [47]. Chronic infection by M. genita-
lium and M. hyorhinis of human prostate cells resulted
in alteration of karyotypes (notably increased polysomy)
and malignant transformation in vitro. Inoculated in
nude mice, these cell lines initiated tumour growth [48].
We have not identified any study concerned with the
clinical association between PCa and Mycoplasma and/
o rU r e a p l a s m a .T oo u rk n o w l e d g e ,w ea r et h ef i r s tt o
report an increased seroprevalence of U. urealyticum
antibodies in PCa patients compared to men with BPH.
Gonorrhoea and syphilis are historically most notorious
STD’s. In a large prospective cohort study of Sutcliffe
et al., gonorrhoea and syphilis were self-reported in 3%
and 0.2%, respectively, and no relationship with PCa was
observed [49]. Self-report of gonorrhoea and/or syphilis
was associated with PCa (OR 1.6, 95% CI 1.2-2.1) in a
Table 5 Overview of previously published case-control serologic studies of genitourinary pathogens with regard to
prostate cancer risk (Continued)
Antilla [7] 2005 Ch.
trachomatis
738 7.5 2271 10.5 OR
0.69
0.51-
0.94
yes* Microimmuno-
fluorescence
Dillner [24] 1998 Ch.
trachomatis
165 10.9 290 10.7 RR
1.04
0.54-
2.00
no Microimmuno-
fluorescence
Hayes [31] 2000 T. pallidum 271 10.7 286 6.3 OR
1.8
1.0-
3.5
yes Microhemagglut-ination
assay (MHA-TP)
Dennis
[27]
2009 HSV 2 267 28.5 267 20.6 OR
1.6
1.05-
2.44
yes ELISA
Huang [26] 2008 HSV 2 765 9.2 915 9.7 OR
0.9
0.7-
1.3
no enzymatic immunodot
assay
Korodi [25] 2005 HSV 2 163 7.2 288 7.5 OR
0.93
0.44-
1.96
no ELISA
Baker [4] 1981 HSV 2 50 68.0 159 51.0 NS NS yes indirect
hemagglutination
inhibition test
Herbert [3] 1976 HSV 2 28 71.4 29 65.5 NS NS no microcomplement
fixation test
Huang [26] 2008 CMV 765 70.3 915 68.4 OR
1.1
0.9-
1.3
no ELISA
OR odds ratio, RR relative risk, CI confidence interval, HPV human papillomavirus, HSV herpes simplex virus, CMV human cytomegalovirus, ELISA Enzyme-linked
Immunosorbent Assay, NS not specified, * inverse association.
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Page 8 of 10study of Hayes et al. Of note, however, serologic evidence
of T. pallidum infection was found in 9.9% vs. 2%
reported (in the black population) and 3.2% vs. 0.1%
reported (in whites) [31]. This fact illustrates how unreli-
able questionnaire and interview-based studies can be
whether for recall bias, unwillingness to report a socially
embarrassing disease such as STD or just by ignorance, i.
e. failing to classify a condition as STD.
Our seroprevalence data for T. pallidum and
N. gonorrhoeae are comparable for PCa and BPH
patients. However, the statistical power is low due to
the small number of patients to draw any reasonable
conclusions.
Every research paper has its limitations and so does
ours. Because blood samples were drawn after the diag-
nosis of PCa, we cannot state whether contact with the
pathogen preceded or followed the evolution of cancer.
T a k i n gB P Hp a t i e n t sa sc o n t r o l sb r i n g st h er i s ko fn o t
coming to a meaningful conclusion if both conditions
had the same (shared) etiology. On the other hand, vir-
tually no healthy prostates exist in the age group our
patients belong to.
Conclusions
T h i si st h ef i r s ts t u d yt oo u rk n o w l e d g et od e m o n -
strate a higher U. urealyticum seroprevalence rate in
PCa patients when compared to BPH controls. HPV
18 and C. trachomatis seropositivity was more com-
mon and the mean CMV antibody levels were higher
in the control (BPH) group than among PCa cases.
Unlike other research groups, we used open surgery-
derived specimens exclusively for all analyses. This
allowed us 1) to minimise the likelihood of misclassi-
fying a tissue sample as benign if cancer was present
and 2) to look for a correlation of PCa and infection
in subgroups of patients depending on local disease
stage. This novel type of analysis did not demonstrate
any differences.
Disregarding inconsistencies of results of the previous
studies, this one adds to the growing body of evidence
that the presence or higher levels of serum antibodies to
most of the genitourinary pathogens studied are not
associated with an elevated PCa risk and/or a more
malignant tumour behavior. Antibody seropositivity to
these infectious agents does not emerge as a risk factor
in screening or treatment decision making. Tissue ana-
lyses focused on viral or bacterial DNA presence could
be a track to run to cast light onto possible association
between PCa and infectious agents.
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